Missouri Trust & Investment Company’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Missouri Trust & Investment Company’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20	Closed	-$2.04K	–	474
2023 Q2	$2.04K	Hold	20	–	–	﹤0.01%	401
2023 Q1	$1.82K	Hold	20	–	–	﹤0.01%	325
2022 Q4	$1K	Hold	20	–	–	﹤0.01%	344
2022 Q3	$1K	Hold	20	–	–	﹤0.01%	355
2022 Q2	$1K	Hold	20	–	–	﹤0.01%	367
2022 Q1	$1K	Hold	20	–	–	﹤0.01%	352
2021 Q4	$1K	Buy	+20	New	+$1.55K	﹤0.01%	399

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Missouri Trust & Investment Company's RETA Position: Q3 2023 in Review

Missouri Trust & Investment Company sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 20 shares — an estimated $2.04K sold.

Missouri Trust & Investment Company first reported a position in RETA in Q4 2021 and held it in 7 quarters. The position peaked at $2.04K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Missouri Trust & Investment Company reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Missouri Trust & Investment Company sold 20 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.04K.
Missouri Trust & Investment Company first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2021 and held it in 7 quarters.
Missouri Trust & Investment Company's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.04K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Missouri Trust & Investment Company's 13F filing for Q3 2023, filed 14 Nov 2023.